Last deal

$200M

Amount

Post-IPO Equity

Stage

17.03.2021

Date

3

all rounds

$445M

Total amount

date founded

Financing round

General

About Company
Rubius Therapeutics develops Red-Cell Therapeutics to treat rare diseases, cancer, and autoimmune diseases.

Industry

Sector :

Subsector :

founded date

01.01.2013

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Rubius Therapeutics was launched by Flagship VentureLabs®, an innovation foundry that systematically evolves enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures. The company's initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. The Phase 1/2 clinical trials of RTX-240 and RTX-224 aim to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of these RCTs in patients with advanced solid tumors.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Kyverna Therapeutics

Kyverna Therapeutics

Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Berkeley, CA, USA

total rounds

3

total raised

$170M
Sonoma BioTherapeutics

Sonoma BioTherapeutics

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

4

total raised

$365M
Pandion Therapeutics

Pandion Therapeutics

Pandion Therapeutics develops novel therapeutics for autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

2

total raised

$138M
Villaris Therapeutics

Villaris Therapeutics

Villaris Therapeutics develops antibody therapeutics for vitiligo and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cary, NC, USA

Financials

Funding Rounds
4
3

Number of Funding Rounds

$445M

Money Raised

Their latest funding was raised on 17.03.2021. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
17.03.2021
$200M
Flagship Pioneering

Flagship Pioneering

Flagship Pioneering creates and grows ventures to transform health and sustainability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

count Of Investments

219

count Of Exists

49
Flagship Pioneering

Flagship Pioneering

Flagship Pioneering creates and grows ventures to transform health and sustainability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

count Of Investments

219

count Of Exists

49
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series A, Series B, Series C
Flagship Pioneering

Flagship Pioneering

Flagship Pioneering creates and grows ventures to transform health and sustainability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

count Of Investments

219

count Of Exists

49

People

Founders
2
Avak Kahvejian
Avak Kahvejian

Avak Kahvejian

Avak Kahvejian joined Flagship Ventures in 2011 as a Partner in VentureLabsTM, bringing nearly 7 years of operational experience in the biomedical tools space. Prior to Flagship, Avak was at Helicos BioSciences, a Flagship VentureLabsTM company which developed and commercialized the world's first single molecule sequencing technology. At Helicos since 2004, Avak held various business development, product management, marketing and sales roles. Most recently, as Vice President, Business Development for Helicos, he focused on establishing strategic partnerships in the areas of high-throughput sequencing and molecular diagnostics, leveraging the technology's unique capabilities. Avak earned his PhD from McGill University in the laboratory of Dr. Nahum Sonenberg, where his research focused on modulators of mRNA translation and their regulation. During his studies at McGill, Avak was awarded a Canadian Institutes of Health Research operating grant as a co-investigator to Dr. Sonenberg, and was selected for the Dean's Honour List upon graduation. At Flagship, Avak is developing new internally-generated ventures as part of VentureLabsTM and he is responsible for marketing and development firm-wide. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.

current job

Ampersand Biomedicines
Ampersand Biomedicines

Avak Kahvejian

Noubar Afeyan
Noubar Afeyan

Noubar Afeyan

Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm's VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.

current job

Omega Therapeutics
Omega Therapeutics

Noubar Afeyan

Employee Profiles
46
Kelly Burke

Kelly Burke

Senior Talent Acquisition Partner

Jiuyi Lu

Jiuyi Lu

Director, Upstream Process Development

Frederico Lourenco

Frederico Lourenco

Senior Director, Corporate Development and Strategy

Lili Wang

Associate director, analytical development

Ashley Case

Principal analyst quality control raw materials

Maiken Keson Brookes

Maiken Keson Brookes

Chief Legal Officer and Corporate Secretary

Alyssa Hoxie

Manager, benefits and human resources operations

Kristian Elverum

Senior vice president of business development and strategy

Activity

Recent News
0